ASCO 2020 | CALGB/SWOG 80702: celecoxib and FOLFOX in stage III colon cancer

Charles Fuchs, MD, MPH, Yale Cancer Center, New Haven, CT, discusses the results from the CALGB/SWOG 80702 study (NCT01150045) which aimed to determine the effect of celecoxib, a COX2 inhibitor, in patients with stage III colon cancer. Despite not resulting in statistically significant improvements in disease free survival, there is still the posibility that aspirin or aspirin-like compounds can have therapeutic value for colon cancer patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).